Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Alternative Names: AT 1331; AT 1412; AT 1413; AT 1628; AT 1630; AT 1636; AT-1219; AT-15226; AT-15260; AT-1613; AT-16201

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AIMM Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Multiple myeloma; Solid tumours
  • Research Colorectal cancer; Liver cancer

Most Recent Events

  • 03 Aug 2017 Preclinical trials in Solid tumours in Netherlands (Parenteral) (AIMM Therapeutics pipeline, August 2017)
  • 01 Aug 2017 Merck & Co. acquires the license to AIMM Therapeutics' anti-cancer monoclonal antibody candidates
  • 26 Apr 2017 Early research in Liver cancer in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top